6.1 Evaluating Outcomes & Revising the Care Plan
Key Takeaways
- Evaluation is the ongoing, cyclical final step of the nursing process that loops back into reassessment, not a one-time judgment made at discharge
- Outcomes are measured against the SMART goals set during planning, using self-report, behavioral observation, standardized rating scales, and lab values
- Standardized scales such as PHQ-9, GAD-7, YMRS, PANSS/BPRS, C-SSRS, AIMS, and CIWA-Ar provide objective, repeatable outcome data across the treatment course
- SSRIs typically require 4 to 6 weeks at an adequate dose before a therapeutic trial can be judged effective or ineffective
- When a goal is not met, the nurse returns to assessment to determine why and revises the plan of care rather than simply continuing an ineffective intervention
Evaluation is the fifth and final step of the nursing process (ADPIE), but on a psychiatric-mental health unit it is never truly "final" — it loops back into assessment and drives every subsequent revision of the plan of care. Domain IV of the PMH-BC blueprint weights Evaluation at only 10%, but the content is high-yield because it tests judgment: can the nurse tell whether an intervention is working, and does the nurse know what to do next if it is not?
The Evaluation Step in the Nursing Process
Evaluation asks a single question for every goal on the care plan: did the patient achieve the expected outcome, partially achieve it, or fail to achieve it? This is not a one-time judgment made at discharge — it is an ongoing, ideally continuous process built into every shift assessment, medication administration, and therapeutic interaction. The nurse compares the patient's current presentation against the measurable, time-limited outcome criteria written into the SMART goals established during planning (see Section 3.3). A goal such as "patient will verbalize no active suicidal ideation for 24 hours" is evaluated in a binary, evidence-based way — either the criterion is met or it is not — which is exactly why SMART goals matter: vague goals cannot be evaluated.
Measuring Outcomes Against the Plan of Care
Outcome measurement draws on several data streams: the patient's self-report, direct behavioral observation, standardized rating instruments, laboratory values, and input from family or the interdisciplinary team. Functional improvement is evaluated alongside symptom reduction — a patient may report fewer depressive symptoms yet still be unable to complete activities of daily living, which signals the plan needs revision even though the "symptom" goal looks met. Evaluation should also track unintended effects: has an intervention introduced new problems (a medication side effect, a new safety risk, a disrupted sleep pattern) that were not part of the original plan?
Standardized Symptom Rating Scales
Repeating a validated rating scale at defined intervals is the most objective way to evaluate treatment response and is heavily tested on the PMH-BC exam.
| Scale | Target Domain | Use in Evaluation |
|---|---|---|
| PHQ-9 | Depression severity | Re-administered periodically; a drop of ≥5 points signals a clinically meaningful response; score <5 suggests remission |
| GAD-7 | Anxiety severity | Tracks symptom trend over the course of treatment |
| YMRS | Manic symptom severity | Serial scores show whether mood stabilization is occurring |
| PANSS / BPRS | Psychotic symptom severity | Tracks positive and negative symptom change with antipsychotic therapy |
| C-SSRS | Suicide risk | Re-administered to track trajectory of risk, not just a single intake score |
| AIMS | Abnormal involuntary movements | Serial use detects emerging tardive dyskinesia in patients on antipsychotics |
| CIWA-Ar | Alcohol withdrawal severity | Guides evaluation of whether symptom-triggered medication dosing is adequate |
A single score is a snapshot; the trend across repeated administrations is what demonstrates whether the plan of care is working.
Evaluating Medication Effectiveness and Adverse Effects
Evaluation of pharmacologic interventions has two parallel tracks: therapeutic response and adverse-effect surveillance. The nurse must know realistic response timelines — for example, SSRIs typically require 4 to 6 weeks at an adequate dose before a full therapeutic effect can be judged, so declaring a trial "failed" at day 10 is a common exam distractor. Evaluation also includes objective monitoring data: lithium levels drawn to confirm the patient remains within the 0.6–1.2 mEq/L therapeutic range, or absolute neutrophil counts confirming clozapine safety. Documented side effects — sedation, weight gain, sexual dysfunction, extrapyramidal symptoms — are weighed against benefit, because adverse effects are the leading cause of medication nonadherence and therefore of relapse.
Recognizing Relapse and Revising the Plan
Part of evaluation is proactively watching for early warning signs of relapse: increasing insomnia, social withdrawal, declining hygiene or school/work performance, medication nonadherence, resurgence of psychotic or mood symptoms, or expressed hopelessness. When evaluation reveals that a goal is not being met, the nursing process does not stop — the nurse returns to assessment to determine why (Was the goal unrealistic? Was the intervention not implemented correctly? Has the patient's condition changed? Is there a new barrier such as cost or side effects?) and then revises the plan of care: adjusting goals, changing interventions, consulting the prescriber about a medication change, or escalating the level of care. This cyclical, non-linear quality is central to the nursing process and distinguishes competent practice from simply carrying out a static list of tasks.
Transitions of Care and Continuity of Evaluation
Evaluation does not stop at discharge. Effective discharge planning includes outcome criteria for the post-discharge period — follow-up appointments scheduled, medication understanding demonstrated with teach-back, a safety plan reviewed, and community resources connected. Evaluating these transition outcomes reduces readmission and is directly tied to the quality-improvement content covered in Section 6.4: a pattern of failed transitions across many patients is itself a quality variance the unit should investigate.
A patient's PHQ-9 score was 19 at admission and is 4 at the two-week follow-up visit. How should the nurse interpret this change when evaluating the plan of care?
A patient has been taking an SSRI at an adequate dose for 10 days with no improvement in depressive symptoms. What is the most appropriate nursing action based on evaluation principles?